Aberrant GSK3β nuclear localization promotes AML growth and drug resistance

James J. Ignatz-Hoover, Victoria Wang, Nathan M. Mackowski, Anne J. Roe, Isaac K. Ghansah, Masumi Ueda, Hillard M. Lazarus, Marcos De Lima, Elisabeth Paietta, Hugo Fernandez, Larry Cripe, Martin Tallman, David N. Wald

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Acutemyeloid leukemia (AML) is a devastatingdisease withpoor patient survival.As targetable mutations in AMLare rare, novel oncogenicmechanisms are needed to define newtherapeutic targets.We identified AML cells that exhibit an aberrant pool of nuclear glycogen synthase kinase 3β (GSK3β). This nuclear fraction drives AML growth and drug resistance. Nuclear, but not cytoplasmic, GSK3β enhances AML colony formation and AML growth in mouse models. Nuclear GSK3β drives AML partially by promoting nuclear localization of the NF-κB subunit, p65. Finally, nuclear GSK3β localization has clinical significance as it strongly correlates to worse patient survival (n=86; hazard ratio=2.2; P<.01) andmediates drug resistance in cell and animal models. Nuclear localization of GSK3β may define a novel oncogenic mechanism in AML and represent a new therapeutic target.

Original languageEnglish (US)
Pages (from-to)2890-2903
Number of pages14
JournalBlood Advances
Volume2
Issue number21
DOIs
StatePublished - Nov 13 2018

Fingerprint

Glycogen Synthase Kinase 3
Drug Resistance
Leukemia
Growth
Survival
Animal Models
Mutation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ignatz-Hoover, J. J., Wang, V., Mackowski, N. M., Roe, A. J., Ghansah, I. K., Ueda, M., ... Wald, D. N. (2018). Aberrant GSK3β nuclear localization promotes AML growth and drug resistance. Blood Advances, 2(21), 2890-2903. https://doi.org/10.1182/bloodadvances.2018016006

Aberrant GSK3β nuclear localization promotes AML growth and drug resistance. / Ignatz-Hoover, James J.; Wang, Victoria; Mackowski, Nathan M.; Roe, Anne J.; Ghansah, Isaac K.; Ueda, Masumi; Lazarus, Hillard M.; Lima, Marcos De; Paietta, Elisabeth; Fernandez, Hugo; Cripe, Larry; Tallman, Martin; Wald, David N.

In: Blood Advances, Vol. 2, No. 21, 13.11.2018, p. 2890-2903.

Research output: Contribution to journalArticle

Ignatz-Hoover, JJ, Wang, V, Mackowski, NM, Roe, AJ, Ghansah, IK, Ueda, M, Lazarus, HM, Lima, MD, Paietta, E, Fernandez, H, Cripe, L, Tallman, M & Wald, DN 2018, 'Aberrant GSK3β nuclear localization promotes AML growth and drug resistance', Blood Advances, vol. 2, no. 21, pp. 2890-2903. https://doi.org/10.1182/bloodadvances.2018016006
Ignatz-Hoover JJ, Wang V, Mackowski NM, Roe AJ, Ghansah IK, Ueda M et al. Aberrant GSK3β nuclear localization promotes AML growth and drug resistance. Blood Advances. 2018 Nov 13;2(21):2890-2903. https://doi.org/10.1182/bloodadvances.2018016006
Ignatz-Hoover, James J. ; Wang, Victoria ; Mackowski, Nathan M. ; Roe, Anne J. ; Ghansah, Isaac K. ; Ueda, Masumi ; Lazarus, Hillard M. ; Lima, Marcos De ; Paietta, Elisabeth ; Fernandez, Hugo ; Cripe, Larry ; Tallman, Martin ; Wald, David N. / Aberrant GSK3β nuclear localization promotes AML growth and drug resistance. In: Blood Advances. 2018 ; Vol. 2, No. 21. pp. 2890-2903.
@article{ea1117f1b9db45a4bf7f65af2527ab19,
title = "Aberrant GSK3β nuclear localization promotes AML growth and drug resistance",
abstract = "Acutemyeloid leukemia (AML) is a devastatingdisease withpoor patient survival.As targetable mutations in AMLare rare, novel oncogenicmechanisms are needed to define newtherapeutic targets.We identified AML cells that exhibit an aberrant pool of nuclear glycogen synthase kinase 3β (GSK3β). This nuclear fraction drives AML growth and drug resistance. Nuclear, but not cytoplasmic, GSK3β enhances AML colony formation and AML growth in mouse models. Nuclear GSK3β drives AML partially by promoting nuclear localization of the NF-κB subunit, p65. Finally, nuclear GSK3β localization has clinical significance as it strongly correlates to worse patient survival (n=86; hazard ratio=2.2; P<.01) andmediates drug resistance in cell and animal models. Nuclear localization of GSK3β may define a novel oncogenic mechanism in AML and represent a new therapeutic target.",
author = "Ignatz-Hoover, {James J.} and Victoria Wang and Mackowski, {Nathan M.} and Roe, {Anne J.} and Ghansah, {Isaac K.} and Masumi Ueda and Lazarus, {Hillard M.} and Lima, {Marcos De} and Elisabeth Paietta and Hugo Fernandez and Larry Cripe and Martin Tallman and Wald, {David N.}",
year = "2018",
month = "11",
day = "13",
doi = "10.1182/bloodadvances.2018016006",
language = "English (US)",
volume = "2",
pages = "2890--2903",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "21",

}

TY - JOUR

T1 - Aberrant GSK3β nuclear localization promotes AML growth and drug resistance

AU - Ignatz-Hoover, James J.

AU - Wang, Victoria

AU - Mackowski, Nathan M.

AU - Roe, Anne J.

AU - Ghansah, Isaac K.

AU - Ueda, Masumi

AU - Lazarus, Hillard M.

AU - Lima, Marcos De

AU - Paietta, Elisabeth

AU - Fernandez, Hugo

AU - Cripe, Larry

AU - Tallman, Martin

AU - Wald, David N.

PY - 2018/11/13

Y1 - 2018/11/13

N2 - Acutemyeloid leukemia (AML) is a devastatingdisease withpoor patient survival.As targetable mutations in AMLare rare, novel oncogenicmechanisms are needed to define newtherapeutic targets.We identified AML cells that exhibit an aberrant pool of nuclear glycogen synthase kinase 3β (GSK3β). This nuclear fraction drives AML growth and drug resistance. Nuclear, but not cytoplasmic, GSK3β enhances AML colony formation and AML growth in mouse models. Nuclear GSK3β drives AML partially by promoting nuclear localization of the NF-κB subunit, p65. Finally, nuclear GSK3β localization has clinical significance as it strongly correlates to worse patient survival (n=86; hazard ratio=2.2; P<.01) andmediates drug resistance in cell and animal models. Nuclear localization of GSK3β may define a novel oncogenic mechanism in AML and represent a new therapeutic target.

AB - Acutemyeloid leukemia (AML) is a devastatingdisease withpoor patient survival.As targetable mutations in AMLare rare, novel oncogenicmechanisms are needed to define newtherapeutic targets.We identified AML cells that exhibit an aberrant pool of nuclear glycogen synthase kinase 3β (GSK3β). This nuclear fraction drives AML growth and drug resistance. Nuclear, but not cytoplasmic, GSK3β enhances AML colony formation and AML growth in mouse models. Nuclear GSK3β drives AML partially by promoting nuclear localization of the NF-κB subunit, p65. Finally, nuclear GSK3β localization has clinical significance as it strongly correlates to worse patient survival (n=86; hazard ratio=2.2; P<.01) andmediates drug resistance in cell and animal models. Nuclear localization of GSK3β may define a novel oncogenic mechanism in AML and represent a new therapeutic target.

UR - http://www.scopus.com/inward/record.url?scp=85067858537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067858537&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2018016006

DO - 10.1182/bloodadvances.2018016006

M3 - Article

C2 - 30385433

AN - SCOPUS:85067858537

VL - 2

SP - 2890

EP - 2903

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 21

ER -